FPR2 and cardiovascular disorder: Interestingly, our results are in line with the research by Qin et al. (2017) [85], in which they showed that other synthetic FPR2 agonists, including compound 43 and compound 17b, also reduced ERK1/2 phosphorylation in a model of cardiovascular disorders.